Myocardial T1 mapping.
Cardiovascular magnetic resonance is a well-established tool for the quantification of focal fibrosis. With the introduction of T1 mapping, diffuse myocardial processes can be detected and quantified. In particular, infiltration and storage disorders with large disease-related changes, and diffuse fibrosis where measurement is harder but the potential impact larger. This has added a new dimension to the understanding and assessment of various myocardial diseases. T1 mapping promises to detect early disease, quantify disease severity and provide prognostic insights into certain conditions. It also has the potential to be a robust surrogate marker in drug development trials to monitor therapeutic response and be a prognostic marker in certain diseases. T1 mapping is an evolving field and numerous factors currently preclude its standardization. In this review, we describe the current status of T1 mapping and its potential promises and pitfalls.
Heart Hospital Imaging Centre, Barts Heart Centre; Hatter Cardiovascular Institute, University College London.
Heerajnarain
H
Bulluck
Viviana
V
Maestrini
Stefania
S
Rosmini
Amna
A
Abdel-Gadir
Thomas A
TA
Treibel
Silvia
S
Castelletti
Chiara
C
Bucciarelli-Ducci
Charlotte
C
Manisty
James C
JC
Moon
D005355:Fibrosis; D006321:Heart / Q000000981:diagnostic imaging*; D006331:Heart Diseases / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008991:Monitoring, Physiologic / Q000379:methods*; D009206:Myocardium / Q000473:pathology*; D011859:Radiography